StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $23.22 | $22.86 | -1.55% | 0.6M |
| 05-15 | $22.83 | $21.97 | -3.77% | 1.0M |
| 05-18 | $21.98 | $21.80 | -0.82% | 1.0M |
| 05-19 | $21.81 | $21.73 | -0.37% | 0.8M |
| 05-20 | $21.90 | $22.24 | +1.55% | 0.9M |
No sell-side coverage available for INVA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $97.99M | $411.33M | $296.71M | $188.91M |
Operating Income | $38.15M | $163.75M | $124.76M | $90.18M |
Net Income | $186.59M | $271.17M | $107.01M | $63.69M |
EPS (Diluted) | $2.22 | $3.30 | $1.35 | $0.24 |
Total Assets | $1.84B | $1.64B | $1.43B | $1.33B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $603.09M | $550.94M | $476.51M | $397.53M |
Free Cash Flow OCF − CapEx | $34.79M | $195.80M | $141.30M | Not available |
Shares Outstanding | 73.81M | 74.64M | 74.77M | 63.01M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.